HASTINGS DAVID C has filed 15 insider transactions across 3 companies since February 2023.
Most recent transaction: a grant/award of 375000 shares of Trevi Therapeutics, Inc. ($TRVI) on January 08, 2026.
Activity breakdown: 0 open-market purchases and 2 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 8, 2026 | Trevi Therapeutics, Inc. | $TRVI | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (right to buy) | 375000 | $0.00 | 375,000.0000 | 145,104,986 | 9999.99% | 0.26% |
| June 26, 2025 | SCYNEXIS INC | $SCYX | HASTINGS DAVID C | Not found | A | Stock Option | 23000 | $0.00 | 23,000.0000 | 48,513,073 | 9999.99% | 0.05% |
| June 26, 2025 | SCYNEXIS INC | $SCYX | HASTINGS DAVID C | Not found | A | Common Stock | 23000 | $0.00 | 69,183.0000 | 48,513,073 | 49.80% | 0.05% |
| Feb. 14, 2025 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (Right to Buy) | 365800 | $0.00 | 365,800.0000 | 0 | 9999.99% | 0.00% |
| Feb. 14, 2025 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | A | Common Shares | 90100 | $0.00 | 249,824.0000 | 0 | 56.41% | 0.00% |
| Feb. 4, 2025 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | S | Common Shares | 22183 | $3.28 | 159,724.0000 | 0 | 12.19% | 0.00% |
| June 20, 2024 | SCYNEXIS INC | $SCYX | HASTINGS DAVID C | Not found | A | Stock Option | 23000 | $0.00 | 23,000.0000 | 48,390,582 | 9999.99% | 0.05% |
| June 20, 2024 | SCYNEXIS INC | $SCYX | HASTINGS DAVID C | Not found | A | Common Stock | 23000 | $0.00 | 46,183.0000 | 48,390,582 | 99.21% | 0.05% |
| Feb. 1, 2024 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (Right to Buy) | 450000 | $0.00 | 450,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2024 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | A | Common Shares | 112500 | $0.00 | 191,500.0000 | 0 | 142.41% | 0.00% |
| Feb. 2, 2024 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | S | Common Shares | 9593 | $2.31 | 181,907.0000 | 0 | 5.01% | 0.00% |
| June 15, 2023 | SCYNEXIS INC | $SCYX | HASTINGS DAVID C | Not found | A | Common Stock | 10000 | $0.00 | 23,183.0000 | 0 | 75.86% | 0.00% |
| June 15, 2023 | SCYNEXIS INC | $SCYX | HASTINGS DAVID C | Not found | A | Stock Option | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | A | Stock Option (Right to Buy) | 316000 | $0.00 | 316,000.0000 | 0 | 9999.99% | 0.00% |
| Feb. 1, 2023 | Arbutus Biopharma Corp | $ABUS | HASTINGS DAVID C | Chief Financial Officer | A | Common Shares | 79000 | $0.00 | 79,000.0000 | 0 | 9999.99% | 0.00% |